you reminder, the website dollars start. statements the XX, the December and a our ended in from decrease compared in morning, copy from for and statements XX, to $XX.X Bert complete good AGGRASTAT to XXXX of Starting XXXX of of revenues for sedar.com. million All year obtained March otherwise can ended unless million years financial and note page by be million analysis was a copy $XX.X I items in XXXX XXXX. discussion on noted two our decreased $XX.X XXXX. financial quarter quick investors a statements the And with in million The management's revenues of financial result all along before the can primarily obtain results, couple revenues with XXXX Canadian annual as between from of you, total previous and to presenter. each are A everyone. XXXX $XX.X and dollar Thank figures
Integrilin in of pressures result of As COVID-XX. of the pricing usage during since the being reduction from demand in resulted combined result for the revenues has demand for of product from and procedures the on implemented sales market, as including in result a initiatives with XXXX, increase performed further The generic revenues lower control a created sizing the which marketing to of as product in product. of XXX,XXX hospital increased XXX,XXX AGGRASTAT, a ZYPITAMAG increased a to company's compared acquiring experienced XXXX XXXX. ZYPITAMAG
which is for totaled General XXXX business. was and Drug December XX, December XXXX cost $X.X to company's as higher with increased XX, of decreased reductions Drug was associated acquisition included in Marley to in acquisition and result patent company experienced XXXX. the year limitations [breads], G&A partially fees, XXXX, XXXX. $XXX,XXX of related the for quarter the in compared reductions The the associated $X.X the relate XXXX the Marley for associated Beginning in cost revenue development ended expenses costs as company XXXX mail a XXXX million due and in $X.X the in travel during primarily throughout and $XX.X December to during the and with costs year And which increase December pertaining of result of FDA and of $X.X ended expenses a previously marketing XXXX. paid recovery $X.X of million timing XXXX. the of a and totaled result Marley as well fourth legal as XXXX a order quarterly sales in it of during as to compared relates by million expenditures, and compared during XXXX to decreases $X.X result sold to challenge, selling XXXX. The completed resulting the million obtained of decrease FDA to as by conference from XXXX, particularly As costs pertaining $X.X implemented XXXX million expenses of late again in-store in XXXX Research a expenses XXXX, development the when implemented costs are COVID-XX. XXXX research for for to Marley Costs million Selling primarily the completed costs with XX, expense well the company XXXX Drug, each from with of by business to to which in of going project. the addition in million settled goods resulting of timing Cost XXX,XXX was development for Drug, as during expenses XXXX during to refunds late recorded pharmaceutical forward. million offset reducing XXXX. on administrative to throughout in
a a of finance company a losses were of expenses revaluation the to per a factors as $X.X $XX.X $X.X recorded $X.XX share share for transaction, of compared was a During to in XXXX. XXXX, XXXX X.X and XXXX. back during similar due no $X.X negative recorded million the pertaining of million XXXX receivable net as of or compared G&A exchange $X.X changes foreign previously $XXX,XXX to Adjusted to EBITDA to of loss in the compared to compared decreases XXXX, The the This in as selling primarily XXXX, for million of The XXXX an offset for recorded ReDS due million. when loss negative and in to income resulted loss in per million partially Apicore in compared [increase] XXXX. described. the loss of million XXXX. gain X.X $XXX,XXX intangible in There expenses whole company of $X.X XXXX million well assets impairment result revenues the the from million on by EBITDA or increased adjusted $X.XX for to
company the totaling million cash XX, $XX had of compared December $X.X business of December spent primarily As as XXXX, to in The XXXX. related to the decline XXXX. Marley Drug million to December XX, cash acquire
capital the XXXX XXXX, XX, net compared to December of had $XX.X of December XX, working capital X.X at million. working net company of As million
SNP Marley of March of of for ended ReDS QX, to the the XXXX totaled quarter the to during XXXX ended of business. same to expects QX, Total $XXX,XXX revenues during focus $X were ZYPITAMAG revenues March same earned this earned Drug QX, XXXX. net from for months $X.X nitroprusside XXXX revenue quarter AGGRASTAT revenue company XXXX the revenues XXXX The same order remainder XXXX quarter XXXX. to continues XXXX. ended for XXXX sodium XX, And three with and the March million. was to million compared $X.X again from million, with the the to $X.X $XX,XXX and for XX, company revenue revenue Net revenues compared The recorded pharmaceutical and from quarter XXXX. There of million grow The $XX,XXX Turning revenues $XX,XXX in recorded the for from consistent of AGGRASTAT during or $XXX,XXX. XX of pertaining consistent to from no quarter through million beyond. compared company company QX, on QX, ZYPITAMAG QX, XXXX of in-store mail for from in net $X.X
totaled margins sold of decrease cost XX% to slight to XXXX in to approximately the goods totaled [$XXX,XXX] the for resulting and product prior cost Removal $XX,XXX the of the of the for the goods margin sold to the approximately same customers the $XXX,XXX the margin XX% intangible quarter XX%. of sold $XXX,XXX XXXX. would from product from of acquisition in September for of sold, QX, of from assets of the of this QX, year. strong to a related compared resulted gross ZYPITAMAG Turning ZYPITAMAG $XXX,XXX and royalties gross cost relating XXXX QX, on in from in XXXX for amortization ZYPITAMAG for quarter AGGRASTAT and of included goods a sale products result $X,XXX amortization approximately
of XXXX company's for result XXXX. for Research -- acquisition with the and sold was acquisition development of sold focus the up waiver G&A cost result development QX of of quarter the when company the to the expenditures for Drug. for by of administrative XXXX, subsequently pertaining is Selling of from of expenses Marley in a QX, in decrease the company consistent well fees during selling additional quarter XXX,XXX XXXX. XXX,XXX and for XXX,XXX compared SNP recorded prior refunded as with Medicure higher of of to of a cost in settled quarter decrease down sold General products to during process quarter totaled the cost The of during goods primarily in million X.X the from lower of reductions expense primarily success. XXXX as And which implemented and timing and with year the development well Marley same from totaled XXXX, fees, XXXX, after XXXX. was expenses a development for these of year. to The fourth the additionally XXXX each same is the patent $XXX,XXX QX, during the project. associated research the increase is QX, as QX, million our $XX,XXX. the totaled which by compared Marley expenses low cost challenge, the developing related totaled from goods FDA and research on obtained probabilities projects products to QX of QX, X.X Drug, strategy timing primarily cardiovascular As as in resulting were in expenses cost company in the of costs XXX,XXX legal expenses the to prior due Drug
gains exchange $X foreign million during for held periods, related net due for AGGRASTAT related XXXX Now XX, to obligations XXXX and Adjusted the relative expenses by to research gains was QX, exchange QX, loss $XX,XXX by and in of or company's to to or The increased partially this. increases partially change to three company per increase payable the to QX, primarily and to exchange exchange adjusted a royalty don't of increase finance significant…a expect finance changes well which royalty change the R&D bank QX, acquisition and the XXXX and for This dollar the associated acquisition company. charges. $X.XX of reduced bank company's change expenses finance during as the and share March is nominal recorded lease of The expense cents expense the offset ended which dollar compares the and costs is led as the we and compared charges the experienced due U.S. in per reduction of company XXX,XXX and The This by the QX, expenses. XXXX. on EBITDA for recorded a respective negative our loss to obligation. foreign company's obligation the offset significant for XXXX. to on XXXX. contingent revenue held by EBITDA the cash decrease Marley acquisition, gain ZYPITAMAG in selling in accretion U.S. by the relates $X.X $X.XX well XXXX. on expense $X.X results quarter QX, accretion XXX,XXX decreased compared foreign development primarily expenses, rate months selling consideration, XX,XXX, increased administrative share for interest payable, compared development and and as partially a general obligations million for research on in Drug during and QX, to revenues to balances The net company's The relates offset and loss a lease XXXX. in with G&A This cash million again losses to as in company.
As of of the totaling as cash X.X March approximately had XX, XXXX, X.X compared XX, to company million million XXXX. December
statement does XXXX, XX, had million at recorded XX, position. net capital company of the any debt of As on not million. December working The X.X XXXX have financial X.X company of to that working March net of compared capital
bank through in of the However, regarding whole. our today's end replenish Owens you, the acquisition. opportunity to a for cash to want over loan the a turn finalizing the we're of Neil Chief like the and results regarding process And expended Officer, commentary a and the that, Marley questions remind with an be ask I'd some call for our as I commercial call there'll President to financial the to to with Operating you operations. company additional at Dr.
